How Does Kliofem Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Kliofem Works
- Active ingredients: Estradiol 2 mg (identical to endogenous oestrogen) and norethisterone acetate 1 mg (a potent progestogen).
- Dual action: Estradiol relieves menopausal symptoms (hot flushes, vaginal dryness) and prevents bone loss; norethisterone protects the uterine lining from oestrogen‑driven overgrowth.
- Continuous combined regimen: Taken daily without a break – avoids monthly withdrawal bleeding and maintains stable hormone levels.
- Metabolism: Both hormones undergo first‑pass hepatic metabolism (CYP3A4 for estradiol; reduction/hydroxylation for norethisterone) and are eliminated via urine and faeces.
- Clinical benefit: Symptom improvement within weeks; osteoporosis prevention with long‑term use.
Kliofem combines bio‑identical estradiol with the progestogen norethisterone acetate to replace declining hormones after menopause. Understanding its chemical structure and metabolic fate helps explain why it effectively relieves symptoms while safeguarding the endometrium.
When to Stop Kliofem and Seek Immediate Help
Stop taking Kliofem and contact a doctor at once if you experience: yellowing of skin/eyes (jaundice), sudden severe headache or migraine‑like symptoms, signs of blood clot (painful leg swelling, sudden chest pain, difficulty breathing), swollen face/tongue/throat (possible angioedema), or a large rise in blood pressure. If you become pregnant, discontinue use immediately.
Chemical Composition & Molecular Structure of Kliofem
Kliofem film‑coated tablets contain two active pharmaceutical ingredients: estradiol (2 mg) and norethisterone acetate (1 mg). Estradiol is micronised 17β‑estradiol, structurally identical to the primary oestrogen secreted by human ovaries. Norethisterone acetate is a synthetic progestogen; after absorption it is rapidly deacetylated to norethisterone, which has high progestogenic and some androgenic activity.
Structural & Physicochemical Properties
estra‑1,3,5(10)‑triene‑3,17β‑diol
Molecular weight 272.38 g/mol. Highly lipophilic (logP 4.0), enabling diffusion across cell membranes and binding to oestrogen receptors (ERα and ERβ) with high affinity.
17β‑hydroxy‑19‑nor‑17α‑pregn‑4‑en‑20‑yn‑3‑one acetate
Prodrug: deacetylated to norethisterone. Molecular weight 340.46 g/mol. Binds to progesterone receptors with potency similar to natural progesterone, and also has weak androgen receptor affinity.
Excipients and Formulation
The tablet core contains lactose monohydrate, maize starch, and magnesium stearate; the film‑coat includes hypromellose, macrogol 400, and titanium dioxide. Lactose may be relevant for patients with rare hereditary galactose intolerance or lactase deficiency.
🗒️ Pharmaceutical insight: The continuous combined dosing (no placebo tablets) ensures daily progestogen exposure, effectively suppressing endometrial proliferation.
Mechanism of Action: How Kliofem Works
Kliofem’s efficacy relies on the complementary actions of its two hormones:
- Estradiol (oestrogen replacement): Estradiol binds to oestrogen receptors (ERα and ERβ) in target tissues such as the hypothalamus, bone, urogenital tract, and blood vessels. The activated receptor complex regulates gene transcription, leading to:
– Suppression of vasomotor instability (reducing hot flushes and night sweats)
– Inhibition of osteoclast activity, thereby slowing bone resorption and preventing osteoporosis
– Restoration of vaginal epithelial thickness and lubrication
– Improvement in skin collagen content and urogenital health - Norethisterone acetate (progestogenic effect): After conversion to norethisterone, it binds to progesterone receptors in the endometrium. This opposes the mitogenic effect of oestrogen, reducing the risk of endometrial hyperplasia and cancer. In the breast, progestogens may counteract some oestrogen‑induced proliferation, though the combined effect on breast cancer risk is well documented.
| Receptor target | Estradiol effect | Norethisterone effect |
|---|---|---|
| Oestrogen receptors (ERα/β) | Agonist – relieves menopausal symptoms, maintains bone density | No direct binding |
| Progesterone receptors | Minimal affinity | Potent agonist – endometrial protection |
| Androgen receptors | – | Weak agonist (may contribute to mood or androgenic side effects) |
🗒️ Physiological insight: By providing continuous combined HRT, Kliofem ensures the endometrium remains thin and inactive, eliminating the need for a withdrawal bleed – a key advantage for postmenopausal women.
Pharmacokinetics: Absorption & Distribution of Kliofem
After oral administration, both hormones are rapidly absorbed from the gastrointestinal tract.
- Estradiol: Peak plasma concentrations (Cmax) occur 4–8 hours post‑dose. Due to extensive first‑pass metabolism, absolute bioavailability is low (~5%). Estradiol binds strongly to sex hormone binding globulin (SHBG) and albumin (≈98% bound).
- Norethisterone: Deacetylated to norethisterone; peak levels at 1–2 hours. Bioavailability is approximately 64% due to first‑pass metabolism. Protein binding is ≈96% (mainly to albumin and SHBG).
Volume of distribution
Estradiol Vd ~1.2 L/kg; norethisterone Vd ~4 L/kg, indicating extensive tissue distribution, particularly in fat, breast, and uterus.
Steady state
With daily dosing, steady‑state levels are achieved within 5–7 days for both components. No accumulation of parent drug occurs due to predictable clearance.
Metabolic Effects & Elimination Pathways of Kliofem
Estradiol metabolism: Primarily hepatic via CYP3A4, converting estradiol to estrone and then to 2‑hydroxyestrone, 16α‑hydroxyestrone, and their sulfates/glucuronides. These conjugates are excreted in urine (60%) and faeces (40%). The elimination half‑life is 13–20 hours.
Norethisterone metabolism: Undergoes reduction (5α‑reductase, 5β‑reductase) and hydroxylation, forming inactive metabolites (mainly sulfates and glucuronides). Excretion is primarily renal (≈50%) and faecal. Half‑life averages 7–9 hours.
⚠️ Metabolic caution: Severe hepatic impairment may prolong half‑lives and increase systemic exposure. Concomitant use of CYP3A4 inducers (e.g., rifampicin, St John’s wort) can reduce efficacy and cause breakthrough bleeding.
Clinical Efficacy: Symptom Relief & Osteoporosis Prevention
Kliofem is indicated for relief of moderate to severe vasomotor symptoms (hot flushes) and for prevention of postmenopausal osteoporosis in women at high risk of fracture when other therapies are unsuitable.
- Symptom control: In randomised trials, continuous combined estradiol/norethisterone significantly reduced frequency and severity of hot flushes within 4 weeks, with maximal improvement by 12 weeks. Quality of life measures (sleep, mood, sexual function) also improve.
- Bone protection: Long‑term use (≥3 years) increases lumbar spine and hip bone mineral density (BMD) by 4–6% compared to placebo, reducing vertebral fracture risk by approximately 30–40%.
- Endometrial safety: The continuous progestogen component reduces endometrial hyperplasia incidence to levels comparable with placebo (<1% after 1 year).
The Women’s Health Initiative (WHI) and other large studies have informed the benefit‑risk profile; current guidance recommends using the lowest effective dose for the shortest duration consistent with treatment goals.
Kliofem FAQs
How long does Kliofem take to start working?
Hot flushes often begin to improve within 2–4 weeks, with full benefit by 3 months. Bone protection requires continuous use for at least 12 months to show measurable gains.
Can I take Kliofem if I still have my womb?
Yes, Kliofem is specifically designed for women with a womb. The norethisterone component protects the endometrium from oestrogen‑induced hyperplasia.
What are the most common side effects of Kliofem?
Very common: breast tenderness and irregular bleeding/spotting (especially in first 3–6 months). Common: headache, nausea, abdominal pain, leg cramps, and fluid retention.
Does Kliofem cause weight gain?
Some women experience mild fluid retention or weight increase, but significant weight gain is not common. Lifestyle factors and ageing are more likely contributors.
Can I use Kliofem if I have a history of breast cancer?
No. Kliofem is contraindicated in women with current, past, or suspected breast cancer. Discuss alternative non‑hormonal options with your specialist.
Need Kliofem with Expert HRT Guidance?
If you are experiencing bothersome menopausal symptoms and would like to explore continuous combined HRT, a UK‑registered doctor can assess your suitability.
Secure Prescription & Next‑Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | Personalised HRT support
Start Menopause ConsultationRelated Kliofem Guides
Medical Content Manager
Nabeel is a co‑founder and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up‑to‑date.
Medical Doctor
Dr. Feroz is a GMC‑registered doctor and a medical reviewer at Chemist Doctor. He oversees menopause and hormone therapy guidance.
Medical Director
Usman is a co‑founder and medical director of Chemist Doctor. He leads the organisation’s strategic vision, bridging clinical and operational priorities.
Review Date: 22 March 2026
Next Review: 22 September 2026
Published on: 22 March 2026
Last Updated: 22 March 2026